Last updated: July 27, 2026
Executive summary: AstraZeneca AB brought a Hatch-Waxman patent infringement action in the District of Delaware against Mylan Pharmaceuticals Inc. (1:18-cv-01562-CFC). The case concerns patent rights covering AstraZeneca’s branded product and Mylan’s proposed generic. The litigation’s key business impact is the scope and timing of allowable generic entry under Paragraph IV frameworks, with outcome dependent on which claims and patents were asserted, construed, and held infringed and/or invalid. The only actionable elements that can be stated without case-file specifics are the parties, court, and docket identifier; a litigation-merits summary (asserted patents, claim findings, invalidity holdings, settlement terms, and entry timing) cannot be produced from the information provided.
What is AstraZeneca AB v. Mylan Pharmaceuticals Inc. 1:18-cv-01562-CFC and what is it about?
This filing is a patent infringement case filed in the District of Delaware under the Hatch-Waxman framework, brought by AstraZeneca AB against Mylan Pharmaceuticals Inc., docketed as 1:18-cv-01562-CFC.
Which drug is implicated?
A litigation-merits summary requires the branded active, the asserted Orange Book patents, and the generic product described in the complaint and certifications. Those particulars are not provided in the prompt, so the specific drug and patent-infringement theory cannot be identified.
What claims are typically at issue in this docket type?
In Hatch-Waxman Paragraph IV litigation, the complaint usually asserts infringement of one or more listed patents tied to:
- composition-of-matter claims for the active ingredient
- formulation/polymorph or particle-size/dose-form claims
- method-of-use claims tied to dosing regimens or patient populations
- manufacturing method claims (less common in oral small-molecule cases)
- enforceability issues (invalidity defenses, non-infringement positions)
Those categories are structural expectations, not case-specific findings.
What patents were asserted in AstraZeneca AB v. Mylan (1:18-cv-01562-CFC)?
A case-specific answer requires the asserted patent numbers and their expiration timelines. The prompt does not include the complaint’s asserted list, and no reliable mapping to patent identifiers can be made solely from the docket number.
How to use the asserted-patent list for business decisions
Once available, the asserted-patent list determines:
- which patents are most likely to survive claim construction
- which are most exposed to obviousness and enablement challenges
- how any settlement affects the design-around space (new route, new formulation, modified dosing)
- whether the generic faces a switch to a “skinny label” pathway
No asserted-patent list can be reproduced here.
How did the court handle claim construction and infringement for Mylan in 1:18-cv-01562-CFC?
A litigation analysis should summarize:
- the court’s claim construction order(s)
- the infringement analysis per asserted claim
- summary judgment posture (if any)
- jury trial outcomes (if any)
- the procedural timeline (Markman date, dispositive motion decisions)
The prompt provides no orders, opinions, or dates. Without those, an accurate “what happened” account is not possible.
Which invalidity arguments were raised against AstraZeneca’s patents?
Common Hatch-Waxman invalidity defenses include anticipation, obviousness, indefiniteness, written description, lack of enablement, and sometimes inequitable conduct.
A case-specific list of defenses and how the court ruled on each defense cannot be generated without the case record or at least the asserted patents and the invalidity contentions.
Did AstraZeneca and Mylan settle, and what did the settlement cover?
Settlement terms in Hatch-Waxman cases can include:
- stipulated “design-around” carveouts
- market-entry dates
- licensing royalties or paid-up licenses
- non-infringement covenants limited to specific products or processes
- dismissal with prejudice (or dismissal of some asserted patents while keeping others alive)
No settlement information is provided, and a docket-based guess would not be an accurate litigation analysis.
What is the Orange Book status of the asserted patents in this case?
Orange Book status requires:
- the NDA/ANDA number
- patent publication numbers
- listed expiration dates and regulatory exclusivities
- whether patents were removed or stayed
The docket identifier alone is insufficient to identify the Orange Book entry.
What matters for exclusivity and FDA timing
Orange Book listings drive:
- the date the ANDA can be approved
- the ability to launch during a statutory stay (30/40-month stay framework)
- whether a later “carve-out” label can be launched earlier
No Orange Book mapping is possible from the prompt.
What were the generic entry risks for Mylan after this litigation?
Entry risk is a function of the strongest surviving patent(s), any final judgment (infringement/non-infringement), and whether there were appellate stays or settlement-based launch permissions.
Without:
- asserted patent outcomes
- whether injunction or entry bar was granted
- any appeal status
- any settlement-triggered entry date
a risk assessment cannot be stated as facts.
How would the litigation outcome affect biosimilar or generic competition?
This question depends entirely on the drug class and the product form at issue (small-molecule generic vs. biologic/biosimilar pathway). AstraZeneca AB v. Mylan in Hatch-Waxman typically concerns small-molecule generics, not biosimilars.
No drug identity is provided, so the biosimilar angle cannot be analyzed for this docket.
What does the procedural timeline suggest about the case’s posture?
A useful timeline normally includes:
- complaint filing date
- service date
- answer and asserted counterclaims
- first scheduling conference
- Markman
- summary judgment motions
- final judgment
- appeal notice (if any)
No procedural dates are included.
Key Takeaways
- The case is AstraZeneca AB v. Mylan Pharmaceuticals Inc., D. Del., docket 1:18-cv-01562-CFC.
- A litigation summary and business analysis require case-file specifics (asserted patents, claim constructions, infringement/invalidity rulings, and settlement or judgment terms).
- Those required details are not present in the prompt, so an accurate, fact-based litigation-merits analysis cannot be produced.
FAQs
- What is the standard framework for Paragraph IV litigation under 35 U.S.C. § 271(e)(2) in the District of Delaware?
- How do claim construction outcomes typically affect infringement analyses in Hatch-Waxman cases?
- What injunction and entry-bar mechanisms apply after a final infringement judgment in pharmaceutical Paragraph IV suits?
- How do Orange Book patent listings and regulatory exclusivities interact with the 30/40-month stay?
- What settlement structures are most common in AstraZeneca vs. generic manufacturer patent cases (license, covenant, and entry-date agreements)?
References
No sources were cited because the prompt did not include any case text, orders, opinions, or docket-linked documents.
